|October 9, 2012|
|09:02 EDT||RHHBY, SGEN||Seattle Genetics to receive milestone payments as Genentech advances two ADCs|
Seattle Genetics (SGEN) will receive undisclosed milestone payments under its antibody-drug conjugate collaboration with Genentech, a member of the Roche Group (RHHBY). The milestones were triggered by Genentech’s advancement of two ADCs utilizing Seattle Genetics technology into phase II clinical development. The phase II randomized, open-label study is designed to evaluate the safety and efficacy of ADCs anti-CD22 and DCDS4501A each in combination with Rituxan in patients with relapsed or refractory follicular non-Hodgkin lymphoma and relapsed or refractory diffuse large B-cell lymphoma.
News For SGEN;RHHBY From The Last 14 Days
|April 17, 2015|
|05:32 EDT||RHHBY||Accelerate Diagnostics appoints Pete Bantock to Chief Culture Officer|
Accelerate Diagnostics (AXDX) appointed Pete Bantock to the newly created position of Chief Culture Officer and Head of Human Resources. Bantock was most recently the SVP and Head of commercial Operations for the Americas. He will be replaced by Ron Price, who joins the company from Roche (RHHBY) where he held the position of VP of Point of Care and Commercial Operations.
|April 16, 2015|
|08:04 EDT||RHHBY||Roche granted orphan status for lymphoma treatment|
The FDA granted Roche's Genentech unit orphan status for Gazyva, its treatment of follicular lymphoma.
|April 14, 2015|
|06:30 EDT||RHHBY||Roche to seek to have cancer drug tested in 11 trials in 2015, Reuters says|
Roche said it would seek to have its immunotherapy cancer drug, MPDL3280A, in 11 late stage trials by the end of 2015, aaccording to Reuters. The drug is being tested in melanoma, as well as lung, bladder, kidney, bowel and blood cancers, the news service noted. Reference Link
|April 13, 2015|
|10:01 EDT||RHHBY||Roche acquires CAPP Medical|
Roche announced it has acquired CAPP Medical, a genomics research company founded by Stanford University oncologists and industry veterans, to advance the development of technology for cancer screening and monitoring through the detection of circulating tumor DNA in blood.
|April 10, 2015|
|07:21 EDT||SGEN||Expert upbeat on Seattle Genetics Adcetris, says RBC Capital|
After meeting with an expert, RBC Capital reports that he believes that off-label use of Seattle Genetics' Adcetris is increasing across a variety of indications. He believes that Adcetris is approvable and has a better chance of becoming a front-line treatment than competing drugs. The firm keeps a $50 price target and Outperform rating on the shares.
|April 8, 2015|
|15:19 EDT||RHHBY||Roche says receives European approval for Avastin plus chemotherapy|
Roche announced that the European Commission approved Avastin -- bevacizumab -- in combination with standard chemotherapy for the treatment of adult patients with persistent, recurrent or metastatic carcinoma of the cervix. The EU approval was based on the significant survival benefit in the pivotal GOG-0240 study, which showed that women who received Avastin plus chemotherapy had a statistically significant 26% reduction in the risk of death, representing a median improvement in survival of nearly four months, compared to women who received chemotherapy alone.
|April 7, 2015|
|07:14 EDT||RHHBY||Eyeforpharma to hold a summit|
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.